Overview

• On June 19, Charleigh Pollock received her final publicly funded Brineura infusion after six years of biweekly treatment
• The British Columbia Ministry of Health halted coverage following a review that found her motor and language scores exceeded discontinuation criteria
• Neurologists and Charleigh’s family contend the therapy still curbs seizures and supports her quality of life
• Experts warn the funding guidelines rely on outdated clinical trial thresholds rather than emerging real-world evidence
• With Brineura expected to clear her system in two weeks, the family is preparing for rapid decline and exploring hospice care